Related Experiment Video
Updated: Aug 30, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant
Jiaxian Chen1, Lin Qi1, Yongxiang Tang2
1Department of Urology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Abstract:
Castration-resistant prostate cancer (CRPC) is a therapy-resistant and lethal form of prostate cancer as well as a therapeutic challenge. Prostate-specific membrane antigen (PSMA) has been proved as a promising molecular target for optimizing the theranostics for CRPC patients. When combined with PSMA radiotracers, novel molecular imaging techniques such as positron emission tomography (PET) can provide more accurate and expedient identification of metastases when compared with conventional imaging techniques. Based on the PSMA-based PET scans, the accurate visualization of local and disseminative lesions may help in metastasis-directed therapy. Moreover, the combination of 68Ga-labeled PSMA-based PET imaging and radiotherapy using PSMA radioligand therapy (RLT) becomes a novel treatment option for CRPC patients. The existing studies have demonstrated this therapeutic strategy as an effective and well-tolerated therapy among CRPC patients. PSMA-based PET imaging can accurately detect CRPC lesions and describe their molecular features with quantitative parameters, which can be used to select the best choice of treatments, monitor the response, and predict the outcome of RLT. This review discussed the current and potential role of PSMA-based imaging and RLT in the diagnosis, treatment, and prediction of prognosis of CRPC.
Insights
Prostate-specific membrane antigen (PSMA) targeted imaging and radioligand therapy (RLT) offer a promising theranostic approach for castration-resistant prostate cancer (CRPC). PSMA-based PET scans accurately detect metastases, guiding treatment and predicting outcomes for CRPC patients.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiochemistry
Background:
- Castration-resistant prostate cancer (CRPC) presents significant therapeutic challenges due to its resistance to conventional treatments.
- Prostate-specific membrane antigen (PSMA) is a validated molecular target for theranostic applications in CRPC.
Purpose of the Study:
- To review the current and potential applications of PSMA-based imaging and radioligand therapy (RLT) in the management of CRPC.
- To highlight the role of PSMA-based positron emission tomography (PET) in identifying metastatic lesions and guiding therapy.
- To discuss the efficacy and tolerability of PSMA-RLT as a treatment option for CRPC.
Main Methods:
- Review of existing literature on PSMA-based PET imaging and RLT for CRPC.
- Analysis of diagnostic accuracy of PSMA-PET compared to conventional imaging.
- Evaluation of clinical outcomes and safety data for PSMA-RLT.
Main Results:
- PSMA-based PET imaging offers superior accuracy in detecting CRPC metastases compared to conventional methods.
- PSMA-RLT has emerged as an effective and well-tolerated treatment for CRPC patients.
- Quantitative parameters from PSMA-PET scans aid in treatment selection, response monitoring, and outcome prediction.
Conclusions:
- PSMA-based theranostics represent a significant advancement in the diagnosis and treatment of CRPC.
- PSMA-PET imaging is crucial for patient stratification and monitoring treatment response to PSMA-RLT.
- Further research into PSMA-based approaches holds potential for improved CRPC management.
More Related Videos
06:54MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019